Processa Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

License Agreement with Ocuphire Pharma, Inc. (Details Narrative) - License Agreement [Member] - Ocuphire Pharma Inc [Member]	Jun. 16, 2021 USD ($) shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock shares issued \| shares	44,689
Cash paid under license agreement	$ 200,000
Liabilities assumed	$ 66,583
Milestone payments, description	Additional consideration includes future development and regulatory milestones payments to Ocuphire upon our achievement of certain defined clinical milestones
Performance of milestone conditions, description	specific diligence milestones that consist of: (i) first patient administered drug in a Clinical Trial of a Product prior to June 16, 2024; and (ii) first patient administered drug in a Pivotal Clinical Trial of a Product or first patient administered drug in a Clinical Trial for a Second Indication of a Product prior to June 16, 2026. Either party may terminate the agreement in the event of a material breach of the agreement that has not been cured following written notice and a 120-day opportunity to cure such breach.